(ORIC) Oric Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 871m USD | Total Return: 39.8% in 12m
Avg Turnover: 11.1M
Qual. Beats: 3
Qual. Beats: 0
Warnings
Share dilution 48.5% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
ORIC Pharmaceuticals, Inc. is a South San Francisco-based biotechnology firm focused on developing therapies to overcome cancer resistance mechanisms. The company’s primary clinical-stage assets include enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR and HER2 exon 20 mutations, and rinzimetostat (ORIC-944), an allosteric PRC2 inhibitor being evaluated for prostate cancer. Both candidates are currently in Phase 1b clinical trials.
The company utilizes a partnership-heavy business model to mitigate risk and facilitate combination therapy research, maintaining active collaborations with Bayer and Johnson & Johnson. In the biotechnology sector, brain-penetrant molecules are highly prioritized for their ability to treat central nervous system metastases, which frequently occur in advanced lung and breast cancers.
For a more comprehensive look at the companys valuation metrics and pipeline potential, consider reviewing the detailed data on ValueRay. Clinical-stage biopharmaceutical companies typically require significant capital expenditures for research and development while generating minimal revenue until a product reaches commercial approval.
- Phase 1b data readouts for enozertinib determine competitive standing in EGFR market
- Clinical trial collaborations with Bayer and J&J validate prostate cancer pipeline
- R&D expenditure levels and cash runway duration influence near term equity valuation
- Regulatory advancement of brain penetrant candidates dictates long term revenue potential
- Success of combination therapies with Nubeqa and Erleada drives investor sentiment
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 22.52 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -110.9m > Net Income -135.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.5m) vs 12m ago 48.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.44%; Δ -0.44% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 290.2m - Total Current Liabilities 17.8m) / Total Assets 436.8m |
| B: -1.67 (Retained Earnings -728.0m / Total Assets 436.8m) |
| C: -0.42 (EBIT TTM -141.8m / Avg Total Assets 339.8m) |
| D: -34.35 (Book Value of Equity -728.3m / Total Liabilities 21.2m) |
| Altman-Z'' = -40.21 = D |
As of May 24, 2026, the stock is trading at USD 8.46 with a total of 626,045 shares traded.
Over the past week, the price has changed by +2.09%,
over one month by -22.75%,
over three months by -28.95% and
over the past year by +39.83%.
Oric Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ORIC.
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.4 | 140.7% |
Revenue TTM = 0.0 USD
EBIT TTM = -141.8m USD
EBITDA TTM = -140.6m USD
Long Term Debt = unknown (none)
Short Term Debt = 3.33m USD (from shortTermDebt, last fiscal year)
Debt = 14.8m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 3.30m
Net Debt = -267.1m USD (calculated: Debt 14.8m - CCE 281.9m)
Enterprise Value = 603.5m USD (870.6m + Debt 14.8m - CCE 281.9m)
Interest Coverage Ratio = unknown (Ebit TTM -141.8m / Interest Expense TTM 0.0)
EV/FCF = -5.42x (Enterprise Value 603.5m / FCF TTM -111.4m)
FCF Yield = -18.45% (FCF TTM -111.4m / Enterprise Value 603.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.22m) / Revenue TTM)
Tobins Q-Ratio = 1.38 (Enterprise Value 603.5m / Total Assets 436.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 14.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -112.0m (EBIT -141.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.33 (Total Current Assets 290.2m / Total Current Liabilities 17.8m)
Debt / Equity = 0.04 (Debt 14.8m / totalStockholderEquity, last quarter 415.6m)
Debt / EBITDA = 1.90 (negative EBITDA) (Net Debt -267.1m / EBITDA -140.6m)
Debt / FCF = 2.40 (negative FCF - burning cash) (Net Debt -267.1m / FCF TTM -111.4m)
Total Stockholder Equity = 382.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.79% (Net Income -135.2m / Total Assets 436.8m)
RoE = -12.17% (Net Income TTM -135.2m / Total Stockholder Equity 1.11b)
RoCE = -33.84% (EBIT -141.8m / Capital Employed (Total Assets 436.8m - Current Liab 17.8m))
RoIC = -79.78% (negative operating profit) (NOPAT -112.0m / Invested Capital 140.4m)
WACC = 13.70% (E(870.6m)/V(885.4m) * Re(13.93%) + D(14.8m)/V(885.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.93% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 30.98%
[DCF] Fair Price = unknown (Cash Flow -111.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.94 | # QB: 3
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.36 | Chg30d=-4.50% | Revisions=-38% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-2.52% | Revisions=-23% | Analysts=14
EPS current Year (2026-12-31): EPS=-1.45 | Chg30d=-3.63% | Revisions=-43% | GrowthEPS=+1.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.55 | Chg30d=-0.15% | Revisions=+0% | GrowthEPS=-6.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -43%